Reducing Skin Damage and Improving Outcomes through Subcutaneous Injection Chambers in Chemotherapy Patients

Patients at risk of extravasation during chemotherapy can benefit from the subcutaneous injection chamber technique, which reduces the risk of skin necrosis and limits drug side effects. Dr. Luu Kinh Khuong, Head of the Department of Anesthesiology and Resuscitation at Tam Anh General Hospital in Ho Chi Minh City, explained that chemotherapy drugs are typically administered through external intravenous lines, which can cause damage to peripheral blood vessels, inflammation, and the risk of extravasation due to vein deviation.

Extravasation is a common complication when injecting drugs into peripheral veins, causing irritation, ulcers, and skin necrosis. Older patients, those with weak vessel walls, obesity, edema or skin lesions are more susceptible to this condition. To address this issue, a subcutaneous injection chamber is often used for patients at risk of extravasation due to chemotherapy at Tam Anh General Hospital. This device is implanted under the skin of the chest wall to support intravenous drug and nutrition infusion, providing a more secure and convenient method of drug delivery.

Patients who undergo the placement of a subcutaneous injection chamber like Ms. Tuyet and Ms. Thao have experienced improved convenience and effectiveness in their cancer treatment. The device allows for targeted delivery of chemotherapy drugs without the risk of complications associated with intravenous administration resulting in reduced side effects and improved outcomes. Patients can continue their treatment with confidence and without the limitations imposed by traditional IV drug delivery methods.

The procedure for implanting a subcutaneous injection chamber involves placing the device under the skin of the chest wall with a catheter inserted into a central vein to facilitate drug delivery. The incision is sutured and bandaged to prevent infection, and patients can resume their daily activities once the device is in place. Regular monitoring and care are required to ensure the longevity and effectiveness of the subcutaneous injection chamber which can last up to 1-2 years before replacement may be necessary.

In conclusion, utilizing subcutaneous injection chambers for patients at risk of extravasation during chemotherapy offers a safe